Guest User

June 21, 2021

Background

AURORA-1: The Sparkling Success in Systemic Lupus Erythematosus

Guest User

June 21, 2021

Background

AURORA-1: The Sparkling Success in Systemic Lupus Erythematosus

The AURORA-1 trial. Sparkling with hope for lupus nephritis. Will this make it easier for rheumatologists to prescribe a CNI? Can you overcome the sticker shock to examine the benefits and weaknesses of AURORA-1. Let’s dive in.

swapnil hiremath

June 8, 2021

Background

One Guideline for all CKD: BP Target 120

swapnil hiremath

June 8, 2021

Background

One Guideline for all CKD: BP Target 120

This week, we will discuss the one guideline to rule them all. KDIGO takes on blood pressure, and simplifies it down to one number. 120.

swapnil hiremath

May 20, 2021

Background

Creativity in Counting with Cluster RCTs

swapnil hiremath

May 20, 2021

Background

Creativity in Counting with Cluster RCTs

This week we discuss cluster RCTs. How do you conduct, consent, analyse and interpret these? Why do you do cluster RCTs? Let’s discuss using the Dial-Mag trial as an example.

swapnil hiremath

May 18, 2021

Background

How Late it was, How Late!

swapnil hiremath

May 18, 2021

Background

This week, we will discuss the (probably) final story in the timing of RRT in AKI story. We discussed ELAIN, AKIKI and STARRT AKI. Early dialysis is not a good idea. But how late can you go? Let’s see with AKIKI-2

joel topf

May 4, 2021

Background

Nephrology Fellowship and COVID-19

joel topf

May 4, 2021

Background

This week, we will discuss the two survey of nephrology trainees regarding their experience with training during the COVID pandemic of 2020-21.

Guest User

April 19, 2021

Background

Advocating for Patients with Vasculitis: A Steroid-Sparing Regimen with Avacopan

Guest User

April 19, 2021

Background

Advocating for Patients with Vasculitis: A Steroid-Sparing Regimen with Avacopan

This week, we will discuss the ADVOCATE trial. Avacopan is not just a flash in the pan? We hope so, having won the RheumMadness and offering a steroid free hope.

swapnil hiremath

April 5, 2021

Background

Terlipressin and Hepatorenal Syndrome: Winning the Battle and Losing the War?

swapnil hiremath

April 5, 2021

Background

Terlipressin and Hepatorenal Syndrome: Winning the Battle and Losing the War?

This week, we will discuss the CONFIRM trial. It was supposed to confirm the role of terlipressin in reversing hepatorenal syndrome…unfortunately it hit the nephrology nihilism wall.

Guest User

March 23, 2021

Background

Spin the Urine! Then Spin it Again!

Guest User

March 23, 2021

Background

This week we’ll be discussing a Kidney 360 paper validating two recent methods of prognostication of AKI by evaluation of the urine sediment.

swapnil hiremath

February 23, 2021

Background

The Roxadustat Chronicles: A Two-Article NephJC

swapnil hiremath

February 23, 2021

Background

The Roxadustat Chronicles: A Two-Article NephJC

The HIF inhibitor trials were announced almost a year and half ago at KidneyWk 2019. We are finally seeing the trials get published. Here are the first two, a sub-group analysis of three dialysis studies focused on incident dialysis patients and a placebo controlled pre-dialysis study.

swapnil hiremath

February 15, 2021

Background

Pragmatic trials in nephrology: Bridging the gap between efficacy and effectiveness?

swapnil hiremath

February 15, 2021

Background

Pragmatic trials in nephrology: Bridging the gap between efficacy and effectiveness?

Join us for the first edition of the #NephTrials chat. Let’s take a deep dive into pragmatic trials, and take a specific example - the Phosphate trial, to anchor the discussion.

joel topf

February 15, 2021

Background

World Kidney Day Chat

joel topf

February 15, 2021

Background

March 11, 2021 is World Kidney Day. Talk about your plans or listen to other people’s plans for the day during this Wednesday’s chat.

swapnil hiremath

February 9, 2021

Background

To Treat or Not to Treat: Bacteriuria in Kidney Transplant Recipients

swapnil hiremath

February 9, 2021

Background

To Treat or Not to Treat: Bacteriuria in Kidney Transplant Recipients

This week we discuss the BiRT trial. It has long been a dogma to treat asymptomatic bacteriuria in kidney transplant recipients. Let’s upend this accepted truth by discussing the BiRT trial.

swapnil hiremath

January 26, 2021

Background

Alerting AKI and Avoiding Adverse Aftermaths

swapnil hiremath

January 26, 2021

Background

Alerting AKI and Avoiding Adverse Aftermaths

This week we discuss the AKi Alert trial from BMJ. Surely alerting us to AKI earlier will be helpful, right? Maybe - or maybe not. Join us to discuss this very important trial with some counter intuitive results.

swapnil hiremath

January 12, 2021

Background

Ponticelli still sparkles in Membranous

swapnil hiremath

January 12, 2021

Background

Was MENTOR the final word for Rituximab in Membranous Nephropathy? Not so. We discuss STARMEN this week which compared sequential tacrolimus- rituximab with the Ponticelli protocol.

swapnil hiremath

December 29, 2020

Background

Renalism Returns with Remdesivir

swapnil hiremath

December 29, 2020

Background

This week, we look at using the, marginally effective, Covid treatment, remdesivir in patients with decreased GFR against the advice of the manufacturer and the FDA.

swapnil hiremath

December 15, 2020

Background

Figuring out fibrosis

swapnil hiremath

December 15, 2020

Background

Glomeruli seem fun and interesting, but the final common pathway for all kidney diseases is fibrosis. Irreversible and relentless once it sets in. Here we discuss some meticulous and groundbreaking work on how this develops, using really cool techniques.

swapnil hiremath

November 24, 2020

Background

Belimumab and Lupus Nephritis: A Marriage made by B Cells?

swapnil hiremath

November 24, 2020

Background

Belimumab and Lupus Nephritis: A Marriage made by B Cells?

This is the first, yes, the first time we are discussing a trial in SLE patients. Belimumab, which inhibits BAFF also called BLyS (hence the BLISS trials) in lupus nephritis. Added to a background of standard therapy - what does it give us? Let’s dive in.

swapnil hiremath

November 9, 2020

Background

Can Finerenone Fiddle the Forgotten A of the RAAS String?

swapnil hiremath

November 9, 2020

Background

Can Finerenone Fiddle the Forgotten A of the RAAS String?

This week, we will discuss whether the time has come to add mineralocorticoid antagonism to the RAS armamentarium. Can we surmount the hyperkalemia which is the commonest problem with these drugs? Let’s find out with FIDELIO.

swapnil hiremath

October 20, 2020

Background

Diabetes and the Kidney

swapnil hiremath

October 20, 2020

Background

This week, we will discuss the fresh-off-the-press KDIGO guidelines on Diabetes. RAS Blockade and SGLT2i, needless to say - but is there more? There is. Read on as we break it down for you.

swapnil hiremath

October 4, 2020

Background

Dapperly Gliding into the Nondiabetic Arena

swapnil hiremath

October 4, 2020

Background

Dapperly Gliding into the Nondiabetic Arena

SGLT2 inhibitors lower MACE in Diabetes. Then they decrease kidney failure in DM. Then Heart Failure in DM and non-DM. And now decrease kidney failure in nonDM too! Let’s see how strong the data really is